Remove In-Vitro Remove In-Vivo Remove Medicine Remove Protein
article thumbnail

Immunotherapy partnership advances space medicine research

Drug Discovery World

US company Vaxxinity and the University of Central Florida (UCF) have announced plans to work together to advance space medicine research. The post Immunotherapy partnership advances space medicine research appeared first on Drug Discovery World (DDW).

article thumbnail

China’s NMPA clears Transcenta’s IND for solid tumour treatment

Pharmaceutical Technology

The Gremlin1 protein was found to promote lineage plasticity while driving castration resistance in prostate cancer. A synergistic activity was also observed between the anti-Gremlin1 antibody and enzalutamide against castration-resistant prostate cancer models derived from patients in vitro and in vivo.

Antibody 242
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Aevitas to sell sCFH asset rights to 4D Molecular

Pharmaceutical Technology

sCFH is an engineered and improved version of complement factor H (CFH) that can fit into adeno-associated virus (AAV) vectors with solid expression and applications confirmed in cultured human cells in vitro, in addition to various preclinical animal models in vivo. The firm will also receive single-digit royalties on net sales.

In-Vivo 130
article thumbnail

Oncotarget: mTORC1 and PLK1 inhibition in adenocarcinoma NSCLC

Scienmag

All these preclinical data strongly suggest that the inhibition of mTORC1 and PLK1 proteins may be a promising therapeutic approach for NSCLC patients Credit: Correspondence to – Didier Decaudin – Didier.decaudin@curie.fr

In-Vivo 96
article thumbnail

News from AACR 2024: Sunday’s highlights

Drug Discovery World

Following this, Benjamin Cravatt, Professor and the Norton Gilula Chair in Biology and Chemistry at The Scripps Research Institute, discussed activity-based protein profiling (ABPP) and its use in discovering drug candidates for cancer-relevant proteins.

In-Vivo 52
article thumbnail

NuChem Sciences becomes part of the Sygnature Group

Drug Discovery World

Founded in 2011, the company delivers discovery solutions across medicinal, synthetic, scale-up, process and computational chemistry, as well as DMPK, in vitro biology and in vivo pharmacology. Previous acquisitions were Peak Proteins in April 2022 and SB Drug Discovery in January 2023.

In-Vivo 52
article thumbnail

Can liquid biopsies transform precision medicine?

Drug Discovery World

Brett Swansiger, Chief Commercial Officer at ANGLE discusses the importance of liquid biopsies in precision medicine trials for cancer. As such there is a need to develop fast and accurate methods to assess drug safety and efficacy, facilitating early success or failure.